



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,074	07/08/2005	Darrell Sleep	11055.204-US	7594
25908 7590 12/22/2010 NOVOZYMES NORTH AMERICA, INC. 500 FIFTH AVENUE SUITE 1600 NEW YORK, NY 10110			EXAMINER GUDIBANDE, SATYANARAYAN R	
			ART UNIT 1654	PAPER NUMBER
			NOTIFICATION DATE 12/22/2010	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

Patents-US-NY@novozymes.com

<i>Examiner-Initiated Interview Summary</i>	Application No. 10/522,074	Applicant(s) SLEEP, DARRELL	
	Examiner SATYANARAYANA R. GUDIBANDE	Art Unit 1654	

All Participants:

(1) SATYANARAYANA R. GUDIBANDE.

(2) Mr. Michael Krenicky.

Date of Interview: 29 November 2010

Type of Interview:

☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
 If Yes, provide a brief description: .

Part I.

Rejection(s) discussed:
102(e)

Claims discussed:
1

Prior art documents discussed:
Hauser (US 2006/0241027)

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:
See Continuation Sheet

Part III.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

Status of Application: _____

(3) _____.

(4) _____.

Time: _____

/SATYANARAYANA R. GUDIBANDE/
 Examiner, Art Unit 1654

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Mr. Krenicky was contactd to discuss the issue of currently maintained 102(e) rejection over Hauser. Mr. Krenicky was informed that the US 2006/0241027 PGPUB claims priority provisional application U.S. 60355547. Although, theafore said provisional application does not disclose the instnatly claimed peptide sequence, the provisional application discloses the identity of the peptide sequence as T-1249. The same nomenclature for the peptide sequence has been used in the aforementioned PG PUB, in the instant application and in the currently pending US Application 12/401,241 that claims priority to the aforementioned provisional application US 60355547. Hence office recommended amending the invntorship in the instnat application to that of the aforementioned US PG PUB or the currently pending US application 12,401,241 both of which has the same inventiove entity and shares a common inventor with the instnat application. No agrrement was reached during the interview.